NVAX - Novavax Stock

Market Summary

USD7.19+0.08

Market Closed

1.13%

NVAX Alerts

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

NVAX Stock Price

NVAX RSI Chart

NVAX Valuation

Market Cap

678.1M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

0.42

EV/EBITDA

-0.32

Price/Free Cashflow

-1.04

NVAX Price/Sales (Trailing)

NVAX Profitability

Operating Margin

53.50%

EBT Margin

-58.15%

Return on Equity

103.76%

Return on Assets

-74.89%

Free Cashflow Yield

-96.46%

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

1.6B

Revenue Y/Y

128.28%

Revenue Q/Q

424.3%

NVAX Earnings

Earnings (TTM)

-586.8M

Earnings Y/Y

111.36%

Earnings Q/Q

119.74%

Price Action

52 Week Range

5.6825.66

(Low)(High)

Last 7 days

2.0%

Last 30 days

-13.9%

Last 90 days

-5.3%

Trailing 12 Months

-64.1%

NVAX Financial Health

Current Ratio

0.51

NVAX Investor Care

Shares Dilution (1Y)

20.69%

Diluted EPS (TTM)

-5.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for NVAX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-09-16	Dubovsky Filip	acquired	97,485	7.71	12,644	president, r&d
2023-09-16	Dubovsky Filip	sold (taxes)	-47,092	7.71	-6,108	president, r&d
2023-08-19	Trizzino John	sold (taxes)	-2,263	7.14	-317	evp, cco and cbo
2023-08-19	Trizzino John	acquired	-	-	655	evp, cco and cbo
2023-08-16	Kelly James Patrick	sold (taxes)	-8,149	7.13	-1,143	evp, cfo and treasurer
2023-08-16	Kelly James Patrick	acquired	-	-	2,366	evp, cfo and treasurer
2023-06-25	Trizzino John	sold (taxes)	-2,700	6.7	-403	evp, cco and cbo
2023-06-25	Trizzino John	acquired	-	-	833	evp, cco and cbo
2023-06-25	Herrmann John A III	acquired	-	-	833	evp, chief legal officer
2023-06-25	Herrmann John A III	sold (taxes)	-1,862	6.7	-278	evp, chief legal officer

Which funds bought or sold NVAX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-09-21	Jefferies Group LLC	new	-	1,274	1,274	-%
2023-09-20	BARCLAYS PLC	added	15.73	780,000	4,023,000	-%
2023-09-12	Farther Finance Advisors, LLC	reduced	-16.67	-9.00	74.00	-%
2023-08-22	Asset Dedication, LLC	unchanged	-	-	-	-%
2023-08-22	COMERICA BANK	new	-	-	-	-%
2023-08-22	VIRGINIA RETIREMENT SYSTEMS ET AL	added	55.79	381,344	950,297	0.01%
2023-08-21	OSAIC HOLDINGS, INC.	added	18.53	120,875	564,727	-%
2023-08-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	3.66	78,002	778,486	-%
2023-08-16	Sunbelt Securities, Inc.	unchanged	-	8.00	74.00	-%
2023-08-16	Nuveen Asset Management, LLC	reduced	-16.95	-229,667	1,868,330	-%

Latest Funds Activity

Are funds buying NVAX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVAX

No. of Funds

Schedule 13G FIlings of Novavax

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 18, 2023	sk bioscience co., ltd.	6.4%	6,500,000	SC 13G
May 10, 2023	state street corp	12.11%	10,452,512	SC 13G/A
Apr 27, 2023	shah capital management	5.28%	4,550,756	SC 13D
Feb 09, 2023	vanguard group inc	10.41%	8,844,653	SC 13G/A
Feb 02, 2023	state street corp	7.15%	6,076,518	SC 13G/A
Feb 01, 2023	blackrock inc.	5.7%	4,808,261	SC 13G/A
Mar 11, 2022	blackrock inc.	5.8%	4,410,761	SC 13G/A
Feb 14, 2022	ra capital management, l.p.	2.8%	2,097,794	SC 13G/A
Feb 08, 2022	blackrock inc.	5.8%	4,410,761	SC 13G
Feb 16, 2021	ra capital management, l.p.	6.0%	3,788,564	SC 13G

Recent SEC filings of Novavax

View All Filings

Date Filed	Form Type	Document
Sep 19, 2023	4	Insider Trading
Aug 22, 2023	4	Insider Trading
Aug 18, 2023	4	Insider Trading
Aug 18, 2023	SC 13G	Major Ownership Report
Aug 08, 2023	S-8	Employee Benefits Plan
Aug 08, 2023	10-Q	Quarterly Report
Aug 08, 2023	424B5	Prospectus Filed
Aug 08, 2023	8-K	Current Report
Aug 08, 2023	8-K	Current Report
Aug 08, 2023	8-K	Current Report

NVAX Fair Value

Loading...

Peers (Alternatives to Novavax)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	143.9B	26.6B	4.85%	20.90%	18.03	5.41	0.75%	21.34%
GILD	94.2B	27.4B	-1.93%	22.79%	17.18	3.44	-0.48%	32.56%
MRNA	37.9B	10.7B	-12.64%	-18.65%	31.39	3.56	-53.67%	-91.41%
BIIB	37.3B	10.0B	-2.84%	30.20%	13.98	3.74	-6.23%	29.40%
MID-CAP
NBIX	11.3B	1.7B	8.03%	13.91%	63.88	6.74	29.01%	1345.90%
BBIO	4.3B	-	-8.13%	165.26%	-7.28	48.33	54.84%	-12.96%
DNLI	3.0B	-	-5.45%	-21.11%	-23.04	37.44	122.90%	54.78%
BEAM	1.9B	80.2M	3.54%	-49.89%	-5.78	23.59	42.17%	-39.82%
SMALL-CAP
RCUS	1.4B	121.2M	-13.83%	-27.58%	-4.86	11.52	-70.36%	-531.73%
REPL	979.0M	15.3M	-20.35%	-0.54%	-5.39	63.94	1090.59%	-36.57%
NVAX	678.1M	1.6B	-13.89%	-64.12%	-1.16	0.42	23.74%	60.24%
FATE	206.9M	-	-21.05%	-90.40%	-0.98	1.51	116.83%	16.61%
VXRT	109.6M	2.1M	-12.14%	-66.77%	-1.09	53.32	487.70%	-8.66%
SGMO	104.5M	-	-28.14%	-88.04%	-0.53	0.43	113.96%	-15.19%
IBIO	3.6M	-	-8.13%	-96.28%	-0.05	3.21	-	-129.46%

Novavax News

Returns for NVAX

Cumulative Returns on NVAX

-19.6%

10-Year Cumulative Returns

-22.8%

7-Year Cumulative Returns

-28.2%

5-Year Cumulative Returns

-60.1%

3-Year Cumulative Returns

Risks for NVAX

What is the probability of a big loss on NVAX?

100%

Probability that Novavax stock will be more than 20% underwater in next one year

100%

Probability that Novavax stock will be more than 30% underwater in next one year.

100%

Probability that Novavax stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVAX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novavax was unfortunately bought at previous high price.

Drawdowns

Financials for Novavax

Income Statement (Last 12 Months)

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	17.6%	1,597,353,000	1,358,852,000	1,981,872,000	1,846,673,000	1,290,940,000	1,403,032,000	1,146,290,000	1,203,749,000	1,181,929,000	919,450,000	475,598,000	204,755,000	50,238,000	18,057,000	18,662,000	15,973,000	21,201,000	28,617,000	34,288,000	38,573,000	39,190,000
Costs and Expenses	-11.9%	2,225,732,000	2,525,648,000	2,626,608,000	3,072,501,000	2,696,723,000	2,671,684,000	2,832,866,000	2,248,207,000	2,113,185,000	1,521,904,000	892,317,000	467,326,000	133,854,000	121,312,000	139,243,000	154,361,000	186,502,000	199,245,000	208,206,000	213,763,000	214,108,000
S&GA Expenses	-2.9%	490,788,000	505,231,000	488,691,000	411,242,000	366,159,000	331,160,000	298,358,000	275,457,000	254,543,000	199,101,000	145,290,000	92,158,000	43,178,000	35,065,000	34,417,000	35,461,000	35,871,000	34,489,000	34,409,000	33,725,000	33,534,000
R&D Expenses	-6.4%	1,028,723,000	1,098,896,000	1,235,278,000	1,940,385,000	2,044,283,000	2,325,320,000	2,534,508,000	1,972,750,000	1,858,642,000	1,322,803,000	747,027,000	375,168,000	99,692,000	95,263,000	113,842,000	127,916,000	150,631,000	164,756,000	173,797,000	180,038,000	180,574,000
EBITDA	100.0%	-	-1,101,787,000	-604,713,000	-1,252,892,000	-1,406,213,000	-1,249,250,000	-1,680,748,000	-1,033,103,000	-914,745,000	-408,196,000	-409,632,000	-411,276,000	-52,755,000	-138,663,000	-137,649,000	-	-	-	-	-	-
EBITDA Margin	100.0%	-	-0.56	-0.31	-0.68	-1.09	-0.89	-1.47	-0.86	-0.77	-0.44	-0.86	-2.01	-1.05	-7.68	-7.38	-	-	-	-	-	-
Interest Expenses	-16.1%	16,210,000	19,320,000	19,880,000	20,417,000	21,430,000	21,164,000	21,127,000	19,868,000	19,146,000	16,581,000	15,145,000	14,669,000	13,612,000	13,612,000	13,612,000	13,612,000	13,612,000	13,612,000	13,612,000	13,732,000	13,849,000
Earnings Before Taxes	49.2%	-585,507,000	-1,152,439,000	-653,647,000	-1,298,813,000	-1,449,062,000	-1,288,764,000	-1,714,536,000	-1,062,425,000	-943,345,000	-612,097,000	-418,259,000	-429,662,000	-70,084,000	-	-132,694,000	-	-	-	-	-	-
EBT Margin	100.0%	-	-0.58	-0.33	-0.70	-1.12	-0.92	-1.50	-0.88	-0.80	-0.47	-0.90	-2.10	-1.40	-8.69	-8.41	-	-	-	-	-	-
Net Income	49.2%	-586,759,000	-1,155,252,000	-657,939,000	-1,321,974,000	-1,475,792,000	-1,317,624,000	-1,743,751,000	-1,075,031,000	-949,910,000	-615,114,000	-418,259,000	-272,525,000	-93,258,000	-115,340,000	-132,694,000	-150,198,000	-176,725,000	-181,614,000	-184,748,000	-186,257,000	-186,294,000
Net Income Margin	100.0%	-	-0.58	-0.33	-0.72	-1.14	-0.94	-1.52	-0.89	-0.80	-0.67	-0.88	-1.33	-1.86	-6.39	-7.11	-	-	-	-	-	-
Free Cashflow	100.0%	-	-653,027,000	-415,937,000	-728,573,000	-	-428,649,000	322,946,000	536,786,000	672,432,000	643,654,000	-42,541,000	62,284,000	36,522,000	-109,126,000	-136,623,000	-158,146,000	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	9.2%	1,685	1,543	2,259	2,267	2,623	2,835	2,577	2,566	2,750	2,608	1,582	944	932	328	173	165	189	221	208	250	286
Current Assets	16.1%	1,128	971	1,703	1,760	2,136	2,347	2,155	2,174	2,355	2,247	1,248	671	636	255	97.00	89.00	110	123	119	161	194
Cash Equivalents	-19.0%	506	625	1,337	1,281	1,388	1,584	1,528	1,947	2,123	2,029	553	402	532	187	82.00	76.00	78.00	106	82.00	75.00	100
Inventory	-31.3%	23.00	34.00	37.00	82.00	256	107	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-2.4%	300	307	294	256	255	247	226	215	213	192	180	132	115	11.00	11.00	12.00	13.00	27.00	28.00	29.00	31.00
Goodwill	-1.1%	128	130	126	118	123	131	131	132	134	131	135	127	119	50.00	51.00	50.00	51.00	51.00	52.00	52.00	52.00
Liabilities	0.1%	2,440	2,438	2,893	2,833	3,040	2,770	2,928	2,105	2,004	1,569	955	638	548	352	359	355	375	372	376	377	374
Current Liabilities	-16.8%	1,596	1,919	2,460	1,668	2,156	2,261	2,390	1,753	1,652	1,209	580	239	213	19.00	26.00	22.00	41.00	31.00	46.00	47.00	43.00
Shareholder's Equity	15.8%	-754	-895	-634	-	-416	65.00	-351	461	746	1,039	627	106	185	-	-	-	-	-	-	-	-
Retained Earnings	1.3%	-4,511	-4,569	-4,275	-4,093	-3,925	-3,414	-3,617	-2,771	-2,449	-2,096	-1,874	-1,696	-1,499	-1,457	-1,431	-1,399	-1,381	-1,342	-1,299	-1,249	-1,205
Additional Paid-In Capital	2.3%	3,856	3,768	3,738	3,641	3,605	3,566	3,352	3,311	3,237	3,180	2,535	1,849	1,699	1,450	1,261	1,226	1,211	1,202	1,145	1,133	1,127
Shares Outstanding	9.3%	94.00	86.00	86.00	78.00	78.00	76.00	76.00	75.00	74.00	73.00	71.00	62.00	59.00	44.00	32.00	23.00	23.00	20.00	18.00	18.00	19.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	-0.2%	-654	-653	-415	-640	-743	-428	323	537	672	644	-42.54	62.00	37.00	-109	-136	-158	-159	-169	-184	-182	-193
Share Based Compensation	-14.1%	108	126	130	135	148	163	184	202	222	177	128	82.00	19.00	15.00	17.00	17.00	19.00	19.00	18.00	21.00	21.00
Cashflow From Investing	16.8%	-82.92	-99.72	-92.98	-87.28	-69.96	-58.28	100	85.00	-3.12	-178	-377	-346	-228	-37.95	38.00	87.00	77.00	27.00	29.00	-2.96	31.00
Cashflow From Financing	29.9%	-132	-189	325	73.00	88.00	45.00	462	927	920	1,376	985	610	645	228	98.00	72.00	61.00	115	103	116	139

NVAX Income Statement

2023-06-30

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Revenues	$ 424,426	$ 185,925	$ 505,377	$ 889,896
Expenses:
Cost of sales	55,777	271,077	89,863	286,281
Research and development	219,475	289,648	466,576	673,131
Selling, general, and administrative	93,717	108,160	206,249	204,152
Total expenses	368,969	668,885	762,688	1,163,564
Income (Loss) from operations	55,457	(482,960)	(257,311)	(273,668)
Other income (expense):
Interest expense	(3,124)	(6,234)	(7,440)	(11,110)
Other income (expense)	5,532	(19,873)	29,894	(18,219)
Income (Loss) before income tax expense (benefit)	57,865	(509,067)	(234,857)	(302,997)
Income tax expense (benefit)	(143)	1,418	1,040	4,080
Net income (loss)	$ 58,008	$ (510,485)	$ (235,897)	$ (307,077)
Earnings Per Share [Abstract]
Basic (in usd per share)	$ 0.65	$ (6.53)	$ (2.69)	$ (3.97)
Diluted (in usd per share)	$ 0.58	$ (6.53)	$ (2.69)	$ (3.97)
Weighted average number of common shares outstanding
Basic (in shares)	89,362	78,143	87,769	77,305
Diluted (in shares)	104,065	78,143	87,769	77,305
Product sales
Revenue:
Revenues	$ 285,163	$ 55,455	$ 277,706	$ 641,083
Grants
Revenue:
Revenues	137,079	107,774	224,458	207,075
Royalties and other
Revenue:
Revenues	$ 2,184	$ 22,696	$ 3,213	$ 41,738

NVAX Balance Sheet

2023-06-30

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 505,912	$ 1,336,883
Restricted cash	10,361	10,303
Accounts receivable	394,890	82,375
Inventory	23,488	36,683
Prepaid expenses and other current assets	192,903	237,147
Total current assets	1,127,554	1,703,391
Property and equipment, net	299,955	294,247
Right of use asset, net	95,739	106,241
Goodwill	128,366	126,331
Other non-current assets	33,434	28,469
Total assets	1,685,048	2,258,679
Current liabilities:
Accounts payable	87,246	216,517
Accrued expenses	458,397	591,158
Deferred revenue	300,473	370,137
Current portion of finance lease liabilities	953	27,196
Convertible notes payable	0	324,881
Other current liabilities	749,186	930,055
Total current liabilities	1,596,255	2,459,944
Deferred revenue	606,937	179,414
Convertible notes payable	167,248	166,466
Non-current finance lease liabilities	30,744	31,238
Other non-current liabilities	38,383	55,695
Total liabilities	2,439,567	2,892,757
Commitments and contingencies (Note 15)
Preferred stock, $0.01 par value, 2,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022.	0	0
Stockholders' deficit:
Common stock, $0.01 par value, 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 95,183,750 shares issued and 94,308,379 shares outstanding at June 30, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December 31, 2022	952	868
Additional paid-in capital	3,855,916	3,737,979
Accumulated deficit	(4,511,786)	(4,275,889)
Treasury stock, cost basis, 875,371 shares at June 30, 2023 and 766,631 shares at December 31, 2022	(91,424)	(90,659)
Accumulated other comprehensive loss	(8,177)	(6,377)
Total stockholders’ deficit	(754,519)	(634,078)
Total liabilities and stockholders’ deficit	$ 1,685,048	$ 2,258,679

Novavax Inc Stock Research

Market Summary

NVAX Alerts

NVAX Stock Price

NVAX RSI Chart

NVAX Valuation

NVAX Price/Sales (Trailing)

NVAX Profitability

NVAX Fundamentals

NVAX Revenue

NVAX Earnings

Price Action

52 Week Range

NVAX Financial Health

NVAX Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for NVAX

Which funds bought or sold NVAX recently?

Latest Funds Activity

NVAX Alerts

Schedule 13G FIlings of Novavax

Recent SEC filings of Novavax

NVAX Fair Value

Peers (Alternatives to Novavax)

Novavax News

Returns for NVAX

Cumulative Returns on NVAX

Risks for NVAX

What is the probability of a big loss on NVAX?

How does NVAX drawdown profile look like?

Financials for Novavax

Income Statement (Last 12 Months)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)

NVAX Income Statement

NVAX Balance Sheet

About Novavax

Market Summary

NVAX Alerts

NVAX Stock Price

NVAX RSI Chart

NVAX Valuation

NVAX Price/Sales (Trailing)

NVAX Profitability

NVAX Fundamentals

NVAX Revenue

NVAX Earnings

Price Action

52 Week Range

NVAX Financial Health

NVAX Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for NVAX

Which funds bought or sold NVAX recently?

Latest Funds Activity

NVAX Alerts

Schedule 13G FIlings of Novavax

Recent SEC filings of Novavax

NVAX Fair Value

Peers (Alternatives to Novavax)

Novavax News

Returns for NVAX

Cumulative Returns on NVAX

Risks for NVAX

What is the probability of a big loss on NVAX?

How does NVAX drawdown profile look like?

Financials for Novavax

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Millions)

NVAX Income Statement

NVAX Balance Sheet

About Novavax

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)